Capricor Therapeutics (CAPR) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed CorMedix (CRMD) over the past year, gaining 32.0% versus a loss of 45.6%. Over five years, CAPR leads with a +122.6% price change compared with +3.9% for CRMD. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $419.2 million), about 1.1 times the size, while CorMedix is growing revenue faster (+617.0% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | CRMD |
|---|---|---|
| Share price | $7.59 | $5.27 |
| Market cap | $441.30M | $419.16M |
| 1-day change | +0.80% | +3.74% |
| YTD return | -73.70% | -54.69% |
| 1-year return | +32.00% | -45.56% |
| 5-year return | +122.58% | +3.94% |
| P/E ratio (TTM) | — | 8.23 |
| Forward P/E | — | 15.06 |
| EPS (TTM) | $-2.65 | $0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $311.71M |
| Revenue growth (YoY) | -100.00% | +617.03% |
| Net income (latest FY) | $-105.04M | $163.06M |
| Gross margin | — | 88.46% |
| Operating margin | — | 48.17% |
| Net margin | — | 52.31% |
| 52-week high | $40.37 | $13.02 |
| 52-week low | $2.96 | $4.47 |
| Distance from 52-week high | -81.20% | -59.52% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +259.03% | +161.86% |
| Average volume | 4.73M | 1.44M |
| Shares outstanding | 58.14M | 79.54M |
| Employees | 231 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed CRMD by 77.6 percentage points over the past year.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -100.00%).
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
CAPR vs CRMD FAQ
Which is bigger, Capricor Therapeutics or CorMedix?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $419.16M for CorMedix (CRMD).
Which stock has performed better over the past year, CAPR or CRMD?
CAPR returned +32.00% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.